Cytori Therapeutics is engaged in the development of cell therapies that are based on autologous adipose-derived regenerative cells (ADRCs) for the treatment of cardiovascular disease and the repairing of soft tissue defects. The company’s scientific data suggests that ADRCs improve blood flow; resultantly, Cytori believes these cells can be applied across multiple ischemic conditions. Through the company’s proprietary technologies and products, these therapies are made available to physicians and patients at the point-of-care. For more information, visit the company’s Web site: http://www.cytori.com
Let us hear your thoughts below: